← Leaderboards
Glen S Kwon
University Of Wisconsin Madison
$5,558,269
Attributed
$5,751,334
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $550.4K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,751,334 · 7
By mechanism
R01$4,742,900 · 4
R21$704,109 · 2
R29$304,325 · 1
Top collaborators
- Suzanne Marie Ponik2 shared
Most similar at University Of Wisconsin Madison
Same institution · by research overlap
- Nizar N Jarjour$24,591,696
- Anant K Menon$12,068,816
Others in their field
Top investigators on “Micelles”
- Timothy P Lodge · Gordon Research Conferences$21,380,000
- Gerhard Wagner · Harvard Medical School$17,534,504
- Vladimir P Torchilin · Northeastern University$13,663,420
- Kit S Lam · University Of California At Davis$12,034,566
- Robert M Stroud · University Of California, San Francisco$10,266,971
- Alexander V Kabanov · University Of Nebraska Medical Center$9,852,258
Research focus
MicellesDrug Delivery SystemsPharmaceutical PreparationsIn VivoSafetyDrug KineticsAntifungal AgentsDrug CombinationsPolymersClinical TrialsToxic EffectAmphotericin BDoseSolubilityBloodTreatment EfficacyBaseEthylene GlycolIn VitroCandidiasisKidneyAntibioticsAreaIntravenous
Grant awards (28)
Oligo(lactic acid)n-Prodrug Nanomedicines for Combination Therapy$330,792
R01 · FY2024 · CA · contact PI
Oligo(lactic acid)n-Prodrug Nanomedicines for Combination Therapy$341,237
R01 · FY2023 · CA · contact PI
Oligo(lactic acid)n-Prodrug Nanomedicines for Combination Therapy$341,237
R01 · FY2022 · CA · contact PI
Direct therapeutic intervention of the tumor microenvironment with a potent inhibitor of fibronectin assembly$209,150
R21 · FY2022 · CA
Oligo(lactic acid)n-Prodrug Nanomedicines for Combination Therapy$347,945
R01 · FY2021 · CA · contact PI
Direct therapeutic intervention of the tumor microenvironment with a potent inhibitor of fibronectin assembly$176,980
R21 · FY2021 · CA
Co-Delivery of Antifungal Agents: Toxicity and Efficacy in Invasive Candidiasis$376,250
R01 · FY2017 · AI · contact PI
Co-Delivery of Antifungal Agents: Toxicity and Efficacy in Invasive Candidiasis$376,250
R01 · FY2016 · AI · contact PI
Co-Delivery of Antifungal Agents: Toxicity and Efficacy in Invasive Candidiasis$376,250
R01 · FY2015 · AI · contact PI
Co-Delivery of Antifungal Agents: Toxicity and Efficacy in Invasive Candidiasis$376,250
R01 · FY2014 · AI · contact PI
Co-Delivery of Antifungal Agents: Toxicity and Efficacy in Invasive Candidiasis$353,675
R01 · FY2013 · AI · contact PI
Tri-modal Polymeric Micelles for 'See & Treat' Applications in Surgical Oncology$174,711
R21 · FY2012 · CA · contact PI
Tri-modal Polymeric Micelles for 'See & Treat' Applications in Surgical Oncology$143,268
R21 · FY2011 · CA · contact PI
Artificial Polymeric Lipoproteins as Drug Carriers$174,805
R01 · FY2010 · AI · contact PI
Artificial Polymeric Lipoproteins as Drug Carriers$140,518
R01 · FY2009 · AI · contact PI
Artificial Polymeric Lipoproteins as Drug Carriers$140,518
R01 · FY2008 · AI · contact PI
Artificial Polymeric Lipoproteins as Drug Carriers$143,240
R01 · FY2007 · AI · contact PI
Artificial Polymeric Lipoproteins as Drug Carriers$139,897
R01 · FY2006 · AI · contact PI
Artificial Polymeric Lipoproteins as Drug Carriers$143,328
R01 · FY2005 · AI
Artificial Polymeric Lipoproteins as Drug Carriers$143,392
R01 · FY2004 · AI
BIOSPECIFIC POLYMER ENZYME CONJUGATES FOR DRUG DELIVERY$130,950
R01 · FY2004 · CA
BIOSPECIFIC POLYMER ENZYME CONJUGATES FOR DRUG DELIVERY$98,213
R01 · FY2003 · CA
Artificial Polymeric Lipoproteins as Drug Carriers$71,727
R01 · FY2003 · AI
ARTIFICIAL POLYMERIC LIPOPROTEINS AS DRUG CARRIERS$105,444
R29 · FY2002 · AI
BIOSPECIFIC POLYMER ENZYME CONJUGATES FOR DRUG DELIVERY$98,213
R01 · FY2002 · CA
ARTIFICIAL POLYMERIC LIPOPROTEINS AS DRUG CARRIERS$101,390
R29 · FY2001 · AI
BIOSPECIFIC POLYMER ENZYME CONJUGATES FOR DRUG DELIVERY$98,213
R01 · FY2001 · CA
ARTIFICIAL POLYMERIC LIPOPROTEINS AS DRUG CARRIERS$97,491
R29 · FY2000 · AI